The CMS Brief (August 2026): Tracking Payment Reform, Greater Accountability, and the Next Phase of Value-Based Care
Every month, CMS releases dozens of announcements, policy updates, proposed rules, and operational guidance documents. Some generate headlines. Others quietly signal where healthcare policy, payment reform, and value-based care may be heading next.
The CMS Brief is designed to help accountable care organizations, value-based care participants, healthcare technology companies, provider groups, and industry stakeholders quickly understand the CMS developments most likely to impact the healthcare landscape.
Here's what happened in August.
As part of the FY 2027 IPPS Final Rule, CMS finalized CJR-X, a nationwide expansion of the Comprehensive Care for Joint Replacement Model. Beginning January 1, 2028, the mandatory model will hold hospitals accountable for cost and quality across episodes involving lower-extremity joint replacements performed in both inpatient and outpatient settings.
Why It Matters: CJR-X adds to a growing portfolio of CMS models that place providers at financial risk for care delivered beyond an individual encounter. For hospitals, ACOs, post-acute providers, and care management organizations, the expansion reinforces the importance of coordinating transitions, monitoring patients after discharge, and managing utilization across the full episode of care.
Read More
On July 31st, CMS published its annual IPPS Final Rule for Fiscal Year 2027, establishing updated payment rates, hospital quality reporting metrics, and social determinants of health (SDoH) coding requirements. The final rule advances CMS’ emphasis on standardized data reporting and quality measurement across acute care networks, while maintaining existing framework requirements for reductions in hospital-acquired conditions.
Why It Matters: The finalized payment updates set the baseline financial parameters for acute care hospitals nationwide. For value-based care models, ACOs, and health systems operating under bundled payments, the IPPS rules directly impact readmission penalty calculations, care transition management, and post-acute coordination strategies.
August 17th marked the deadline for public comments on CMS's proposed rule codifying the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program. Transitioning from administrative guidance to formal regulation, the rule details how maximum fair prices (MFPs) will be applied, compliance expectations for manufacturers and other stakeholders, and oversight measures to prevent product restructuring.
Why It Matters: As negotiated prices for initial drug cohorts take effect and subsequent negotiation cycles roll out, pharmaceutical manufacturers, pharmacy benefit managers (PBMs), and health plans face a rapidly evolving pricing architecture. Value-based organizations managing total cost of care must re-evaluate drug formulary dynamics and specialty pharmacy expenditure modeling.
With the public comment window closing for the CY 2027 Medicare Physician Fee Schedule Proposed Rule, stakeholders across health tech and primary care mounted a coordinated response regarding proposed restrictions on outsourced Remote Patient Monitoring (RPM) clinical staff, new billing codes, and future AI reimbursement frameworks. Organizations submitted extensive feedback urging CMS to maintain flexible care management workflows while defining sustainable pathways for AI-driven clinical tools.
Why It Matters: The upcoming final rule, expected in late fall, will determine whether primary care practices need to restructure their RPM/RTM workflows and how AI technologies will be integrated into future fee schedules and value-based care incentives.
As we head into September, we will be tracking CMS’s analysis of public feedback submitted on the MPFS and OPPS proposed rules, updates on ACO REACH performance results, and additional implementation guidance on 2027 interoperability and prior authorization mandates.
We'll be back next month with another edition of The CMS Brief.